Les infections peuvent-elles aggraver la dégradation des ARNm ?
Certaines infections virales peuvent exacerber les symptômes liés à la dégradation des ARNm.
Infections viralesSymptômes
#4
Le mode de vie a-t-il un impact sur les risques ?
Un mode de vie sain peut réduire certains risques, mais ne prévient pas toutes les maladies.
Mode de viePrévention des maladies
#5
Les facteurs génétiques sont-ils déterminants ?
Oui, les mutations génétiques jouent un rôle clé dans la dégradation des ARNm non-sens.
Facteurs génétiquesMutations
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Dégradation des ARNm non-sens : Questions médicales les plus fréquentes",
"headline": "Dégradation des ARNm non-sens : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Dégradation des ARNm non-sens : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-07",
"dateModified": "2025-05-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Dégradation des ARNm non-sens"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maturation post-transcriptionnelle des ARN",
"url": "https://questionsmedicales.fr/mesh/D012323",
"about": {
"@type": "MedicalCondition",
"name": "Maturation post-transcriptionnelle des ARN",
"code": {
"@type": "MedicalCode",
"code": "D012323",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.308.700"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Dégradation des ARNm non-sens",
"alternateName": "Nonsense Mediated mRNA Decay",
"code": {
"@type": "MedicalCode",
"code": "D059365",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Lynne E Maquat",
"url": "https://questionsmedicales.fr/author/Lynne%20E%20Maquat",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, USA."
}
},
{
"@type": "Person",
"name": "Luísa Romão",
"url": "https://questionsmedicales.fr/author/Lu%C3%ADsa%20Rom%C3%A3o",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisboa, Portugal. luisa.romao@insa.min-saude.pt."
}
},
{
"@type": "Person",
"name": "Fabrice Lejeune",
"url": "https://questionsmedicales.fr/author/Fabrice%20Lejeune",
"affiliation": {
"@type": "Organization",
"name": "Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France."
}
},
{
"@type": "Person",
"name": "Paulo J da Costa",
"url": "https://questionsmedicales.fr/author/Paulo%20J%20da%20Costa",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisboa, Portugal."
}
},
{
"@type": "Person",
"name": "Tatsuaki Kurosaki",
"url": "https://questionsmedicales.fr/author/Tatsuaki%20Kurosaki",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Conventional endoscopic mucosal resection versus modified endoscopic mucosal resection for duodenal neuroendocrine tumor.",
"datePublished": "2023-01-30",
"url": "https://questionsmedicales.fr/article/36717428",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00464-023-09885-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anchoring endoscopic mucosal resection versus conventional endoscopic mucosal resection for large nonpedunculated colorectal polyps: a randomized controlled trial.",
"datePublished": "2022-06-24",
"url": "https://questionsmedicales.fr/article/35750321",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-1884-7849"
}
},
{
"@type": "ScholarlyArticle",
"name": "Standard Endoscopic Mucosal Resection vs Precutting Endoscopic Mucosal Resection Using Novel Disk-Tip Snare for Colorectal Lesions.",
"datePublished": "2023-03-07",
"url": "https://questionsmedicales.fr/article/36881195",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10620-023-07833-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of cold snare endoscopic mucosal resection and hot snare endoscopic mucosal resection for small colorectal polyps: a randomized controlled trial.",
"datePublished": "2024-09-02",
"url": "https://questionsmedicales.fr/article/39223224",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-71067-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatment of adenoma recurrence after endoscopic mucosal resection.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37414440",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/gutjnl-2023-330300"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Régulation de l'expression des gènes",
"item": "https://questionsmedicales.fr/mesh/D005786"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maturation post-transcriptionnelle des ARN",
"item": "https://questionsmedicales.fr/mesh/D012323"
},
{
"@type": "ListItem",
"position": 5,
"name": "Dégradation des ARNm non-sens",
"item": "https://questionsmedicales.fr/mesh/D059365"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Dégradation des ARNm non-sens - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Dégradation des ARNm non-sens",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Dégradation des ARNm non-sens",
"description": "Comment diagnostiquer la dégradation des ARNm non-sens ?\nQuels tests sont utilisés pour évaluer la dégradation des ARNm ?\nQuels marqueurs biologiques indiquent une dégradation non-sens ?\nPeut-on détecter la dégradation des ARNm par imagerie ?\nQuel rôle joue la bioinformatique dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Endoscopic+Mucosal+Resection#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Dégradation des ARNm non-sens",
"description": "Quels symptômes sont associés à la dégradation des ARNm non-sens ?\nLa dégradation des ARNm peut-elle causer des douleurs ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Endoscopic+Mucosal+Resection#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Dégradation des ARNm non-sens",
"description": "Peut-on prévenir la dégradation des ARNm non-sens ?\nY a-t-il des mesures préventives recommandées ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes tests génétiques peuvent-ils prévenir des maladies ?\nLa sensibilisation est-elle importante pour la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Endoscopic+Mucosal+Resection#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Dégradation des ARNm non-sens",
"description": "Quels traitements existent pour la dégradation des ARNm non-sens ?\nLes thérapies géniques sont-elles efficaces ?\nY a-t-il des médicaments spécifiques pour cette condition ?\nLes traitements sont-ils personnalisés ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Endoscopic+Mucosal+Resection#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Dégradation des ARNm non-sens",
"description": "Quelles complications peuvent survenir ?\nLa dégradation des ARNm peut-elle entraîner des cancers ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles réversibles ?\nComment les complications sont-elles traitées ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Endoscopic+Mucosal+Resection#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Dégradation des ARNm non-sens",
"description": "Quels sont les facteurs de risque associés ?\nL'environnement influence-t-il la dégradation des ARNm ?\nLes infections peuvent-elles aggraver la dégradation des ARNm ?\nLe mode de vie a-t-il un impact sur les risques ?\nLes facteurs génétiques sont-ils déterminants ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Endoscopic+Mucosal+Resection#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la dégradation des ARNm non-sens ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et l'analyse des ARNm par RT-PCR."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la dégradation des ARNm ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme le Northern blot et la séquençage d'ARN sont couramment utilisées."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques indiquent une dégradation non-sens ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'augmentation des ARNm contenant des mutations non-sens est un indicateur clé."
}
},
{
"@type": "Question",
"name": "Peut-on détecter la dégradation des ARNm par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne permet pas de détecter directement la dégradation des ARNm."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la bioinformatique dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bioinformatique aide à analyser les séquences d'ARN et à identifier les mutations non-sens."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à la dégradation des ARNm non-sens ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon la maladie sous-jacente, incluant fatigue et troubles neurologiques."
}
},
{
"@type": "Question",
"name": "La dégradation des ARNm peut-elle causer des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs peuvent survenir en raison de maladies génétiques associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez les signes de dysfonctionnement organique ou neurologique."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains individus peuvent être asymptomatiques malgré la dégradation des ARNm."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps, selon la gravité de la condition sous-jacente."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la dégradation des ARNm non-sens ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives recommandées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques peuvent être utiles pour les familles à risque."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais ne prévient pas directement."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des maladies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent d'identifier les porteurs de mutations et de prendre des mesures."
}
},
{
"@type": "Question",
"name": "La sensibilisation est-elle importante pour la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sensibilisation aux maladies génétiques peut aider à un diagnostic précoce."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour la dégradation des ARNm non-sens ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies géniques et des médicaments ciblant les ARNm."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques sont-elles efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles montrent des résultats prometteurs, mais leur efficacité dépend de la maladie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments spécifiques pour cette condition ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les modulateurs d'ARN peuvent être utilisés pour cibler les ARNm."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires varient, incluant des réactions allergiques et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques et des maladies dégénératives."
}
},
{
"@type": "Question",
"name": "La dégradation des ARNm peut-elle entraîner des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations peuvent augmenter le risque de cancers, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications chroniques peuvent affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles traitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement des complications dépend de leur nature et peut inclure des thérapies ciblées."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque associés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux de maladies génétiques et des mutations spécifiques."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il la dégradation des ARNm ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent interagir avec des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la dégradation des ARNm ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent exacerber les symptômes liés à la dégradation des ARNm."
}
},
{
"@type": "Question",
"name": "Le mode de vie a-t-il un impact sur les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire certains risques, mais ne prévient pas toutes les maladies."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques sont-ils déterminants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations génétiques jouent un rôle clé dans la dégradation des ARNm non-sens."
}
}
]
}
]
}
Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA.
Publications dans "Dégradation des ARNm non-sens" :
Department of Molecular Genetics, The Ohio State University, Columbus, OH 43210, USA; Center for RNA Biology, The Ohio State University, Columbus, OH 43210, USA. Electronic address: singh.734@osu.edu.
Publications dans "Dégradation des ARNm non-sens" :
As the incidence of duodenal neuroendocrine tumors (DNET) is steadily increasing, the role of endoscopic treatment for appropriate lesions is becoming more significant. We aimed to compare the outcome...
Patients who underwent endoscopic treatment for DNET between June 2000 and December 2019 were included. The clinicopathologic features and treatment outcomes were investigated by reviewing medical rec...
Overall, 104 cases underwent endoscopic resection for nonampullary DNET, including conventional EMR (n = 57), cap-assisted EMR (EMR-C, n = 19), and precut EMR (EMR-P, n = 28). The en bloc resection ra...
Conventional EMR and modified EMR are feasible and effective for the treatment of nonampullary DNET sized < 10 mm and limited to mucosal and submucosal layer. Additionally, endoscopists should be awar...
BACKGROUND : Colorectal polyps > 10 mm in size are often incompletely resected. Anchoring-endoscopic mucosal resection (A-EMR) is the technique of making a small incision at the oral side of the polyp...
SOUTEN (KANEKA Co., Tokyo, Japan) is a unique snare with a disk tip. We analyzed the efficacy of precutting endoscopic mucosal resection with SOUTEN (PEMR-S) for colorectal lesions....
We retrospectively reviewed 57 lesions of 10-30 mm treated with PEMR-S at our institution from 2017 to 2022. The indications were lesions that were difficult for standard EMR due to size, morphology, ...
The polyp size was 16.5 ± 4.2 mm and the non-polypoid morphology rate was 80.7%. Histopathological diagnosis included 10 sessile-serrated lesions, 43 low-grade and high-grade dysplasias, and 4 T1 canc...
PEMR-S achieved high en bloc resection of colorectal lesions of 20-30 mm though it leaded to long procedure time....
Incomplete resection rates vary among endoscopists performing cold snare polypectomy. Cold snare endoscopic mucosal resection (CS-EMR) is the technique of cold resection after submucosal injection to ...
Residual or recurrent adenoma (RRA) after endoscopic mucosal resection (EMR) of large non-pedunculated colorectal polyps (LNPCPs) of ≥20 mm is a major limitation. Data on outcomes of the endoscopic tr...
Over 139 months, detailed morphological and histological data on consecutive RRA detected after EMR for single LNPCPs at one tertiary endoscopy centre were prospectively recorded during structured sur...
213 (14.6%) patients had RRA (168 (78.9%) at first surveillance and 45 (21.1%) thereafter). RRA was commonly 2.5-5.0 mm (48.0%) and unifocal (78.7%). Of 202 (94.8%) cases which had macroscopic evidenc...
RRA after EMR of LNPCPs can be effectively treated using simple endoscopic techniques with long-term adenoma remission of >90%; only 16% required retreatment. Therefore, more technically complex, morb...
NCT01368289 and NCT02000141....
Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) allow endoscopic resection of early esophageal adenocarcinoma. The choice between the two techniques takes into account th...
Patients who underwent an endoscopic resection for esophageal adenocarcinomas between March 2015 and December 2019 were included. ESD was compared to EMR in terms of clinical, procedural, histologic, ...
85 patients were included: 57 ESD and 28 EMR. The median (IQR) diameter of the lesion was 20(15-25) mm in the ESD group, and 15(8-16) mm in the EMR group, p<0.01. ESD allowed en bloc resection in 100%...
ESD was as safe as EMR and allowed higher en bloc, R0 and curative resection rates. Although these results did not translate into long-term outcomes, these data prompt for a broader adoption of ESD fo...
As endoscopic mucosal resection (EMR) of large (≥ 20 mm) adenomatous nonpedunculated colonic polyps (LNPCPs) becomes widely practiced outside expert centers, appropriate training is necessary to avoid...
Consecutive EMRs were recruited from a single center over 130 months. Lesion characteristics, intraprocedural data, and adverse events were recorded. Challenging lesions with intraprocedural bleeding ...
Of 1993 LNPCPs, 286 (14.4 %) were in challenging locations (anorectal junction, ileocecal valve, or appendiceal orifice), 368 (18.5 %) procedures were complicated by IPB and 77 (3.9 %) by IPP; 110 (5....
The EMR-CSS is a novel case selection tool for conventional EMR training, which identifies a subset of adenomatous LNPCPs that can be successfully and safely attempted in early EMR training....
Underwater endoscopic mucosal resection (UEMR) is increasingly applied in the treatment of superficial non-ampullary duodenal epithelial tumors (SNADETs). This meta-analysis aimed to assess the effica...
The following electronic databases were searched from 2012 until November 20, 2021: PubMed, Embase, Scopus, Web of Science databases, and Cochrane Library. The primary outcomes were the rates of en bl...
A total of 6 studies with 679 lesions (331 underwent UEMR and 348 CEMR) were included in this study. The pooled analysis showed that UMER achieves a similar en bloc resection rate (87.6 vs. 89.9%; odd...
This meta-analysis demonstrated that UEMR appears to be an effective and safe alternative to CEMR for SNADETs ≤20 mm....
The aim of this study is to evaluate and compare the safety and efficacy of endoscopic mucosal resection with a cap (EMR-c) with those of endoscopic submucosal dissection (ESD) for rectal neuroendocri...
A total of 122 patients who underwent EMR-c or ESD for R-NETs at the Fourth Hospital of Hebei Medical University between February 2007 and December 2020 were invovled in this study. The clinical outco...
A total of 122 patients with 128 R-NETs underwent endoscopic resection (EMR-c, 80; ESD, 48). In terms of duration of operation, EMR-c was significantly shorter than ESD (p < 0.001). Univariate analysi...
Both EMR-c and ESD were safe and effective treatments for R-NETs ≤ 15 mm in diameter. In addition, tumor diameter ≥ 8 mm was an independent risk factor for incomplete resection....
Although gel immersion endoscopic resection (GIER) is a potential alternative to underwater endoscopic mucosal resection (UEMR) for superficial nonampullary duodenal epithelial tumors (SNADETs), compa...
40 consecutive procedures performed in 35 patients were retrospectively reviewed; the primary outcome was procedure time, and the secondary outcomes were en bloc and R0 resection rates, tumor and spec...
Lesions were divided into GIER (n = 22) and UEMR groups (n = 18). The median (range) procedure time was significantly shorter in the GIER group than in the UEMR group (2.75 [1-3.5] minutes vs. 3 2 3 4...
GIER is efficacious and safe to treat SNADETs, although additional studies are needed....